Humana Inc. (NYSE:HUM) Stake Reduced by Tredje AP fonden

Tredje AP fonden reduced its stake in shares of Humana Inc. (NYSE:HUM) by 24.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 30,483 shares of the insurance provider’s stock after selling 10,000 shares during the period. Tredje AP fonden’s holdings in Humana were worth $7,734,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC bought a new position in Humana during the 3rd quarter worth $31,000. FPC Investment Advisory Inc. bought a new position in Humana during the 4th quarter worth $27,000. Centricity Wealth Management LLC bought a new position in Humana during the 4th quarter worth $30,000. OFI Invest Asset Management bought a new position in Humana during the 4th quarter worth $33,000. Finally, Atwood & Palmer Inc. grew its stake in Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Trading Up 0.9 %

Shares of NYSE HUM opened at $251.32 on Friday. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a market cap of $30.33 billion, a price-to-earnings ratio of 25.26, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business has a fifty day simple moving average of $271.56 and a 200-day simple moving average of $281.21.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.41%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s payout ratio is 35.58%.

Insider Activity at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Morgan Stanley reduced their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. Barclays boosted their price target on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Piper Sandler boosted their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. reduced their price target on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Nineteen analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.